Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
The Board Trustees Of The University Of Arkansas is currently managing 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This prosecution activity is limited to 1 distinct examiner and 1 distinct art unit. The busiest examiner for the company is TIEN, LUCY MINYU, who is responsible for the 1 pending office action currently on record.
The concentration of the portfolio into 1 distinct art unit suggests a specific technical focus within the Biotechnology & Pharmaceuticals sector. Because only 1 distinct examiner is involved, the university's current patent strategy is highly dependent on the individual review of TIEN, LUCY MINYU. This examiner's handling of the active action will determine the immediate progress of the university's intellectual property in this area.
Practitioners overseeing this portfolio face a centralized prosecution environment. With 1 pending office action, there are no competing priorities or differing examiner styles to manage at this time. The focus remains entirely on the active case within the designated art unit to secure patent rights for The Board Trustees Of The University Of Arkansas.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| TIEN, LUCY MINYU | 1 | 59.1% | +36.8% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18095418 | FENCLORIM SEED TREATMENT AS A BIOSTIMULANT | TIEN, LUCY MINYU | 91d overdue |
| Art Unit | Apps |
|---|---|
| 1612 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18095418 | FENCLORIM SEED TREATMENT AS A BIOSTIMULANT | TIEN, LUCY MINYU | 1612 | §103DP | Non-Final OA | 91d overdue | Pending | Jan 10, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialThe Board Trustees Of The University Of Arkansas has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Lucy Minyu Tien has the most, with 1 of The Board Trustees Of The University Of Arkansas's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
